A Personalized Treatment for Lung Cancer: Molecular Pathways, Targeted Therapies, and Genomic Characterization

William P. Luke, F. Griffith Pearson, Thomas R.J. Todd, G. Alec Patterson, Joel D. Cooper, Prospective evaluation of mediastinoscopy for assessment of carcinoma of the lung. The Journal of Thoracic and Cardiovascular Surgery. ,vol. 91, pp. 53- 56 ,(1986) , 10.1016/S0022-5223(19)38480-6

, Reduced lung-cancer mortality with low-dose computed tomographic screening. The New England Journal of Medicine. ,vol. 365, pp. 395- 409 ,(2011) , 10.1056/NEJMOA1102873

Irene Brüske-Hohlfeld, Environmental and occupational risk factors for lung cancer. Methods of Molecular Biology. ,vol. 472, pp. 3- 23 ,(2009) , 10.1007/978-1-60327-492-0_1

James Chih-Hsin Yang, Martin H. Schuler, Nobuyuki Yamamoto, Kenneth John O'Byrne, Vera Hirsh, Tony Mok, Sarayut Lucien Geater, Sergey V Orlov, Chun-Ming Tsai, Michael J. Boyer, Wu-Chou Su, Jaafar Bennouna, Terufumi Kato, Vera Gorbunova, Ki Hyeong Lee, Riyaz N.H. Shah, Dan Massey, Robert M. Lorence, Mehdi Shahidi, Lecia V. Sequist, LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology. ,vol. 30, pp. LBA7500- LBA7500 ,(2012) , 10.1200/JCO.2012.30.15_SUPPL.LBA7500

M. G. Kris, B. E. Johnson, D. J. Kwiatkowski, A. J. Iafrate, I. I. Wistuba, S. L. Aronson, J. A. Engelman, Y. Shyr, F. R. Khuri, C. M. Rudin, E. B. Garon, W. Pao, J. H. Schiller, E. B. Haura, K. Shirai, G. Giaccone, L. D. Berry, K. Kugler, J. D. Minna, P. A. Bunn, Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC). Journal of Clinical Oncology. ,vol. 29, ,(2011) , 10.1200/JCO.2011.29.15_SUPPL.CRA7506

Stephen L. Graziano, Gary P. Gamble, Nancy B. Newman, Lynn Z. Abbott, Michelle Rooney, Sulagna Mookherjee, Melissa L. Lamb, Leslie J. Kohman, Bernard J. Poiesz, Prognostic Significance of K-ras Codon 12 Mutations in Patients With Resected Stage I and II Non–Small-Cell Lung Cancer Journal of Clinical Oncology. ,vol. 17, pp. 668- 668 ,(1999) , 10.1200/JCO.1999.17.2.668

Philip C Prorok, Gerald L Andriole, Robert S Bresalier, Saundra S Buys, David Chia, E David Crawford, Ronald Fogel, Edward P Gelmann, Fred Gilbert, Marsha A Hasson, Richard B Hayes, Christine Cole Johnson, Jack S Mandel, Albert Oberman, Barbara O'Brien, Martin M Oken, Sameer Rafla, Douglas Reding, Wilmer Rutt, Joel L Weissfeld, Lance Yokochi, John K Gohagan, FACE for the PLCO Project Team, Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial Controlled Clinical Trials. ,vol. 21, pp. 273- ,(2000) , 10.1016/S0197-2456(00)00098-2

Marta Puyol, Alberto Martín, Pierre Dubus, Francisca Mulero, Pilar Pizcueta, Gulfaraz Khan, Carmen Guerra, David Santamaría, Mariano Barbacid, A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma Cancer Cell. ,vol. 18, pp. 63- 73 ,(2010) , 10.1016/J.CCR.2010.05.025

L. V. Sequist, B. A. Waltman, D. Dias-Santagata, S. Digumarthy, A. B. Turke, P. Fidias, K. Bergethon, A. T. Shaw, S. Gettinger, A. K. Cosper, S. Akhavanfard, R. S. Heist, J. Temel, J. G. Christensen, J. C. Wain, T. J. Lynch, K. Vernovsky, E. J. Mark, M. Lanuti, A. J. Iafrate, M. Mino-Kenudson, J. A. Engelman, Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Science Translational Medicine. ,vol. 3, ,(2011) , 10.1126/SCITRANSLMED.3002003

Joshua A. Roth, Josh J. Carlson, Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis. Clinical Lung Cancer. ,vol. 12, pp. 393- 401 ,(2011) , 10.1016/J.CLLC.2011.04.005